

Covance Health Economics and Outcomes Services

[View the current Covance Health Economics and Outcomes Services Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/3033-Covance+Health+Economics+and+Outcomes+Services.html)

(<http://www.bioportfolio.com/biocorporate/3033-Covance+Health+Economics+and+Outcomes+Services.html>)

Contact Details:

1100 New York Avenue, NW, Suite 200
Washington
DC
20005-3934
United States of America

Tel: 202 637 6870
Fax: 202 637 6690
Email:

Recent Publications by Covance Health Economics and Outcomes Services:



- [The burden of neuropathic pain: results from a cross-sectional survey.](#)
*BACKGROUND: There are few published data on the treatment patterns and...*9th June, 2006
Covance Health Economics and Outcomes Services Inc., 9801 Washington- Eur J Pain. 2006
Feb;10(2):127-35. ([DOI Direct Link](#))
- [The inequity of informal payments for health care: the case of Hungary.](#)
*As in most countries of Central and Eastern Europe, informal payments have...*3rd March, 2006
Covance Health Economics and Outcomes Services, Springfield House, Hyde- Health Policy. 2006
Feb;75(3):262-71. ([DOI Direct Link](#))
- [Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003.](#)
*OBJECTIVES: The objective of this study was to review and analyze the use...*8th November, 2005
Covance Health Economics and Outcomes Services, London, UK.- Value Health. 2005
Sep-Oct;8(5):534-48. ([DOI Direct Link](#))
- [Cost-effectiveness of a targeted disinfection program in household kitchens to prevent foodborne illnesses in the United States, Canada, and the United Kingdom.](#)
*Foodborne illnesses impose a substantial economic and quality-of-life...*9th January, 2004
Covance Health Economics and Outcomes Services Inc., 4225 Executive Square- J Food Prot. 2003
Nov;66(11):2103-15.

- [Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.](#)
*BACKGROUND: Although use of long-acting opioid analgesics has increased...*6th December, 2003
Covance Health Economics and Outcomes Services Inc., Gaithersburg, MD- J Manag Care Pharm. 2003 May-Jun;9(3):223-31.
- [The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma.](#)
*The aim of this study was to compare the quality-of-life (QOL) effects of...*10th September, 2003
Covance Health Economics and Outcomes Services Inc., 9th Floor, 9801- Support Care Cancer. 2003 May;11(5):304-12. Epub 2003 Jan 28. ([DOI Direct Link](#))
- [The cost-effectiveness of beta-radiation therapy for treatment of in-stent restenosis: an analysis at 290-day follow-up.](#)
*PURPOSE: We studied the cost-effectiveness of percutaneous coronary...*23rd August, 2003
Covance Health Economics and Outcomes Services, 9801 Washingtonian- Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):107-13.
- [Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.](#)
*Gastroesophageal reflux disease (GERD) is characterized by heartburn and...*5th June, 2003
Covance Health Economics and Outcomes Services Inc., Gaithersburg,- Dig Dis Sci. 2003 Apr;48(4):657-62.
- [Economic evaluation of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion: an evidence-based modeling approach.](#)
*STUDY DESIGN: Economic evaluation provides a framework to explicitly...*26th November, 2002
Covance Health Economics and Outcomes Services, Gaithersburg, Maryland,- Spine. 2002 Aug 15;27(16 Suppl 1):S94-9.

BioNews Results for Covance Health Economics and Outcomes Services



- [Erin M. Sullivan Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Reimbursement & Health Economics](#)
Pharma Live: Oct 7 2008 6:11PM Matching: covance health economics outcomes services

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic

- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

